Lin BioScience Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2019
Selling, General & Admin	356.55	242.75	124.26	93.52	51.99	Upgrade
Research & Development	1,101	854.07	320.87	244.76	145.01	Upgrade
Operating Expenses	1,458	1,097	445.13	338.28	196.99	Upgrade
Operating Income	-1,458	-1,097	-445.13	-338.28	-196.99	Upgrade
Interest Expense	-1	-1.2	-0.88	-0.07	-0.25	Upgrade
Interest & Investment Income	122.52	4.49	1.19	0.19	0.5	Upgrade
Currency Exchange Gain (Loss)	-	-1.95	8.87	-0.53	-0.14	Upgrade
Other Non Operating Income (Expenses)	7.83	4.95	-41.93	-151.95	22.09	Upgrade
EBT Excluding Unusual Items	-1,328	-1,091	-477.87	-490.63	-174.8	Upgrade
Gain (Loss) on Sale of Assets	-	-	-	0.22	-	Upgrade
Pretax Income	-1,328	-1,091	-477.87	-490.41	-174.8	Upgrade
Income Tax Expense	-69.6	-29.72	-18.44	-9.51	-22.95	Upgrade
Earnings From Continuing Operations	-1,259	-1,061	-459.43	-480.9	-151.84	Upgrade
Minority Interest in Earnings	514.45	373.63	145.91	46.21	-	Upgrade
Net Income	-744.27	-687.19	-313.52	-434.7	-151.84	Upgrade
Net Income to Common	-744.27	-687.19	-313.52	-434.7	-151.84	Upgrade
Shares Outstanding (Basic)	79	74	72	69	62	Upgrade
Shares Outstanding (Diluted)	79	74	72	69	62	Upgrade
Shares Change (YoY)	6.22%	3.14%	4.27%	10.73%	4.42%	Upgrade
EPS (Basic)	-9.47	-9.29	-4.37	-6.32	-2.44	Upgrade
EPS (Diluted)	-9.47	-9.29	-4.37	-6.32	-2.44	Upgrade
Free Cash Flow	-1,025	-1,015	-383.4	-291.96	-181.18	Upgrade
Free Cash Flow Per Share	-13.04	-13.72	-5.34	-4.24	-2.92	Upgrade
EBITDA	-1,437	-1,091	-442.62	-336.79	-195.83	Upgrade
D&A For EBITDA	20.21	5.85	2.51	1.48	1.17	Upgrade
EBIT	-1,458	-1,097	-445.13	-338.28	-196.99	Upgrade

Updated Aug 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.